1102 related articles for article (PubMed ID: 17349996)
21. Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine.
Walker EA; Young AM
J Pharmacol Exp Ther; 2002 Jul; 302(1):101-10. PubMed ID: 12065706
[TBL] [Abstract][Full Text] [Related]
22. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox.
Zernig G; Butelman ER; Lewis JW; Walker EA; Woods JH
J Pharmacol Exp Ther; 1994 Apr; 269(1):57-65. PubMed ID: 8169852
[TBL] [Abstract][Full Text] [Related]
23. mu-Opioid receptor downregulation contributes to opioid tolerance in vivo.
Stafford K; Gomes AB; Shen J; Yoburn BC
Pharmacol Biochem Behav; 2001; 69(1-2):233-7. PubMed ID: 11420091
[TBL] [Abstract][Full Text] [Related]
24. Mu-opioid receptor down-regulation and tolerance are not equally dependent upon G-protein signaling.
Gomes BA; Shen J; Stafford K; Patel M; Yoburn BC
Pharmacol Biochem Behav; 2002 May; 72(1-2):273-8. PubMed ID: 11900797
[TBL] [Abstract][Full Text] [Related]
25. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox.
Barrett AC; Smith ES; Picker MJ
J Pharmacol Exp Ther; 2003 Jun; 305(3):1061-70. PubMed ID: 12649297
[TBL] [Abstract][Full Text] [Related]
26. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Sterious SN; Walker EA
J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
[TBL] [Abstract][Full Text] [Related]
27. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
Kögel B; Christoph T; Strassburger W; Friderichs E
Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
[TBL] [Abstract][Full Text] [Related]
28. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
[TBL] [Abstract][Full Text] [Related]
29. Spinal interaction between the highly selective μ agonist DAMGO and several δ opioid receptor ligands in naive and morphine-tolerant mice.
Szentirmay AK; Király KP; Lenkey N; Lackó E; Al-Khrasani M; Friedmann T; Timár J; Gyarmati S; Tóth G; Fürst S; Riba P
Brain Res Bull; 2013 Jan; 90():66-71. PubMed ID: 22995282
[TBL] [Abstract][Full Text] [Related]
30. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
31. Activation of delta-opioid receptor contributes to the antinociceptive effect of oxycodone in mice.
Yang PP; Yeh GC; Yeh TK; Xi J; Loh HH; Law PY; Tao PL
Pharmacol Res; 2016 Sep; 111():867-876. PubMed ID: 27496654
[TBL] [Abstract][Full Text] [Related]
32. Etorphine elicits anomalous excitatory opioid effects on sensory neurons treated with GM1 ganglioside or pertussis toxin in contrast to its potent inhibitory effects on naive or chronic morphine-treated cells.
Crain SM; Shen KF
Brain Res; 1996 Nov; 741(1-2):275-83. PubMed ID: 9001733
[TBL] [Abstract][Full Text] [Related]
33. Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists.
Abul-Husn NS; Sutak M; Milne B; Jhamandas K
Br J Pharmacol; 2007 Jul; 151(6):877-87. PubMed ID: 17502848
[TBL] [Abstract][Full Text] [Related]
34. The effect of intrinsic efficacy on opioid tolerance.
Duttaroy A; Yoburn BC
Anesthesiology; 1995 May; 82(5):1226-36. PubMed ID: 7741298
[TBL] [Abstract][Full Text] [Related]
35. MGM-9 [(E)-methyl 2-(3-ethyl-7a,12a-(epoxyethanoxy)-9-fluoro-1,2,3,4,6,7,12,12b-octahydro-8-methoxyindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate], a derivative of the indole alkaloid mitragynine: a novel dual-acting mu- and kappa-opioid agonist with potent antinociceptive and weak rewarding effects in mice.
Matsumoto K; Takayama H; Narita M; Nakamura A; Suzuki M; Suzuki T; Murayama T; Wongseripipatana S; Misawa K; Kitajima M; Tashima K; Horie S
Neuropharmacology; 2008 Aug; 55(2):154-65. PubMed ID: 18550129
[TBL] [Abstract][Full Text] [Related]
36. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors.
Smith PA; Selley DE; Sim-Selley LJ; Welch SP
Eur J Pharmacol; 2007 Oct; 571(2-3):129-37. PubMed ID: 17603035
[TBL] [Abstract][Full Text] [Related]
37. Clocinnamox dose-dependently antagonizes morphine-analgesia and [3H]DAMGO binding in rats.
Paronis CA; Woods JH
Eur J Pharmacol; 1997 Oct; 337(1):27-34. PubMed ID: 9389377
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the antinociceptive effect of acute morphine in female and male Sprague-Dawley rats using the long-lasting mu-antagonist methocinnamox.
Peckham EM; Barkley LM; Divin MF; Cicero TJ; Traynor JR
Brain Res; 2005 Oct; 1058(1-2):137-47. PubMed ID: 16139823
[TBL] [Abstract][Full Text] [Related]
39. Ultra-low dose naloxone upregulates interleukin-10 expression and suppresses neuroinflammation in morphine-tolerant rat spinal cords.
Lin SL; Tsai RY; Tai YH; Cherng CH; Wu CT; Yeh CC; Wong CS
Behav Brain Res; 2010 Feb; 207(1):30-6. PubMed ID: 19799935
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
Lester PA; Traynor JR
Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
